SG Americas Securities LLC purchased a new position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 20,295 shares of the company's stock, valued at approximately $199,000.
A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Erste Asset Management GmbH acquired a new position in shares of Ginkgo Bioworks during the 3rd quarter worth $4,075,000. Jacobs Levy Equity Management Inc. acquired a new stake in Ginkgo Bioworks in the 3rd quarter valued at about $2,282,000. PFG Investments LLC acquired a new stake in Ginkgo Bioworks in the 3rd quarter valued at about $1,541,000. BNP Paribas Financial Markets acquired a new stake in Ginkgo Bioworks in the 3rd quarter valued at about $1,287,000. Finally, PDT Partners LLC acquired a new stake in Ginkgo Bioworks in the 3rd quarter valued at about $1,199,000. 78.63% of the stock is owned by institutional investors and hedge funds.
Ginkgo Bioworks Stock Performance
NYSE DNA traded down $0.07 during trading hours on Wednesday, reaching $12.31. The company's stock had a trading volume of 1,767,045 shares, compared to its average volume of 1,577,483. The company has a market cap of $707.57 million, a PE ratio of -0.94 and a beta of 1.16. Ginkgo Bioworks Holdings, Inc. has a fifty-two week low of $5.26 and a fifty-two week high of $64.40. The business's 50-day moving average price is $11.12.
Ginkgo Bioworks Company Profile
(
Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Further Reading
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
